The StoneBreakerTM Trial

NCT ID: NCT00677196

Last Updated: 2010-09-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-02-29

Study Completion Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the LMA StoneBreakerTM to the current standard of pneumatic lithotripsy, the Swiss LithoClastR, during percutaneous nephrolithotripsy (PNL).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective:

The purpose of this study is to compare the LMA StoneBreakerTM to the current standard of pneumatic lithotripsy, the Swiss LithoClastR, during percutaneous nephrolithotripsy (PNL).

Rationale:

Percutaneous nephrolithotripsy (PNL) is the preferred treatment modality for renal stones greater than 2cm in diameter.

The pneumatic lithotriptor functions as a pneumatic jackhammer, providing either a single pulse or a train of pulses at 2Hz as determined by the operator. Its chief advantage is its ability to fragment even the hardest calculi. The pneumatic lithotriptor, while extremely effective, does not utilize thermal energy and therefore has no risk of thermal damage to the surrounding tissue. The pneumatic lithotriptor currently in use, the Swiss LithoClast is powered by compressed medical air. The primary disadvantage of this device is that the residual calculi must be individually removed with forceps following fragmentation.

The StoneBreaker, manufactured by the Laryngeal Mask Airway Company, is a novel hand-held pneumatic lithotriptor. This device is powered by a compressed carbon dioxide cartridge.

Hypothesis:

The LMA StoneBreaker, provides more efficient lithotripsy of renal calculi treated by PNL over the existing pneumatic intracorporeal lithotriptor the Swiss LithoClast.

Methods:

Patients would be recruited to the study from the clinical population who present for stone management at VGH. None of the physicians involved has a financial interest in either of the devices being evaluated. The purpose is to compare the pneumatic lithotripsy devices and is not an evaluation of PNL, a procedure whose safety and efficacy is well established.

Patients who consented to PNL for management of their renal stone would be approached about entry into the study by either of the primary surgeons, the research coordinator, or the research fellows. Patients would understand that PNL is not an experimental procedure and that the research project specifically is comparing the two lithotripsy devices with similar mechanism of action and safety profile. The goal in all cases would be to render the patient stone free. The patients care would not deviate from our standard PNL care protocol, summarized below, with the exception of the use of a different lithoclast.

Pre-operatively, the patients are assessed in the Preanaesthetic clinic as necessary. Blood tests including CBC and differential, blood type and antibody screen, creatinine and electrolytes are routinely obtained. Urine samples will be sent preoperatively for culture and sensitivity. If the urine culture is positive, organism specific antibiotics will be prescribed prior to treatment. If the urine culture is negative, prophylactic antibiotics will be ordered and administered, prior to the induction of anaesthesia, by the treating surgeon.

Our standard operative protocol for PNL as described next will be followed for all cases. After receiving a general anaesthetic, cystoscopy and placement of a ureteral catheter on the affected side may be performed. The will be used to perform retrograde pyelography in order to determine the optimal access site to the kidney. A Foley catheter will be placed to drain the bladder throughout the procedure. Next, under fluoroscopic guidance, access to the affected renal collecting system will be obtained with a needle down which a guide wire is passed by the interventional radiology department or the operating surgeon.

The tract will be dilated to accommodate the 30F working sheath. The stone will then be visualized and fragmented with either of the two devices, determined by randomization. Remaining fragments will be removed using grasping forceps and an ultrasound suction device until the patient is rendered stone free. A final visual inspection of the collecting system will ensure the patient is stone free. The choice of renal drainage method after the procedure will be left to the discretion of the treating surgeon.

Statistical Analysis: Student's t-test and ANOVA will be used to determine statistical significance. P-values \< 0.05 will be considered significant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Percutaneous Nephrolithotripsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

The LMA StoneBreakerTM

Group Type ACTIVE_COMPARATOR

The stonebreaker arm (LMA Stonebreaker)

Intervention Type DEVICE

The interventional device name is the LMA Stonebreaker pneumatic handheld lithotriptor.

2

Pneumatic Lithotripsy

Group Type ACTIVE_COMPARATOR

Pneumatic Lithotripsy (Swiss LithoClastR)

Intervention Type DEVICE

Pneumatic lithotripsy, the Swiss LithoClastR during percutaneous nephrolithotripsy (PNL)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The stonebreaker arm (LMA Stonebreaker)

The interventional device name is the LMA Stonebreaker pneumatic handheld lithotriptor.

Intervention Type DEVICE

Pneumatic Lithotripsy (Swiss LithoClastR)

Pneumatic lithotripsy, the Swiss LithoClastR during percutaneous nephrolithotripsy (PNL)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over the age of 18 undergoing PNL
* Previously untreated renal stones
* Patients with 3 or less individual renal calculi, accessible with a rigid nephroscope
* Stones must be at least \>225mm2 area on KUB
* Patient must have a CT scan prior to treatment

Exclusion Criteria

* Patients with an active contraindication for PNL (pregnancy, uncorrected coagulopathy, active urinary infection, contrast allergy)
* Partial staghorn calculi
* Complete staghorn calculi
* Stones in calyceal diverticulum
* Cases requiring multiple tracts
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of British Columbia

OTHER

Sponsor Role lead

VGH and UBC Hospital Foundation

OTHER

Sponsor Role collaborator

Vancouver Coastal Health

OTHER_GOV

Sponsor Role collaborator

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University of British Columbia

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ben Chew, MD, FRCSC

Role: PRINCIPAL_INVESTIGATOR

University of British Columbia

R. Paterson, MD

Role: STUDY_DIRECTOR

University of British Columbia

J. Wright, MD

Role: STUDY_DIRECTOR

University of British Columbia

J. Teichman, MD

Role: STUDY_DIRECTOR

University of British Columbia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vancouver General Hospital

Vancouver, British Columbia, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H07-01887

Identifier Type: -

Identifier Source: org_study_id